Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.50    -0.10 (-3.85%)
Bid:
2.50
Ask:
2.60
Spread: 0.10 (4.00%)
Market Cap: £2.58m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Board Updates

2 Jul 2020 10:42

RNS Number : 8591R
Litigation Capital Management Ltd
02 July 2020
 

2 July 2020

 

Litigation Capital Management Limited

(LCM or the Company)

 

Board Updates

 

Litigation Capital Management Limited (AIM:LIT), specialist alternate asset manager and a leading international provider of disputes financing solutions, provides the following update:

 

· LCM currently looking to expand the geographic market reach of its Non-Executive Directors in line with LCM's business plan

· Steve McLean steps down as non-executive director as part of this upcoming Board realignment

· Minor delays in the CEO relocating to London due to COVID-19

 

LCM is at an advanced stage in the search to add additional Non-Executive Directors (NED) to the Board. As the Company strengthens its market positioning in the Northern Hemisphere, including the UK and Europe, as well as transitioning its management to the London office, it looks to new NED appointments to bring significant experience in these markets. As part of this upcoming restructuring, Steve McLean has kindly agreed to resign his position on the board effective as at 30 June 2020.

 

Steve was appointed to LCM's board as a NED prior to the Company's IPO on the Australian Securities Exchange. Steve brought with him significant in-region equity capital markets experience and has been a very valuable member of LCM's board during the building of its business, particularly in the APAC region.

 

LCM expects to be in a position to make an announcement as to a new Non-Executive board member in the near future.

 

Jonathan Moulds, Chairman of LCM, commented: "Steve has been a strong supporter of LCM through two IPOs, one on the Australian Securities Exchange and then on the London Stock Exchange:AIM as a Non-Executive board member. As LCM's business expands into new global markets, it will benefit from board experience in those large economies. We will continue to have access to Steve and his experience was a long-term supporter of the business. I thank him for his significant contribution to the growth of LCM over a number of years"

 

Enquiries

 

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

 

 

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

 

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

 

 

 

Alma PR

Tel: 020 3405 0205

Rebecca Sanders-Hewett

LCM@almapr.co.uk

Justine James

 

David Ison

 

 

NOTES TO EDITORS

 

Litigation Capital Management (LCM) is a global provider of disputes finance which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is fund and/or asset management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Corporate portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

LCM has an unparalleled track record, driven by effective project selection, active project management and robust risk management.

 

Headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOASSUSUEESSEDW
Date   Source Headline
12th Dec 20237:00 amRNSTransaction in Own Shares
11th Dec 20237:00 amRNSTransaction in Own Shares
8th Dec 20237:00 amRNSTransaction in Own Shares
7th Dec 20237:00 amRNSTransaction in Own Shares
6th Dec 20237:00 amRNSTransaction in Own Shares
5th Dec 20237:00 amRNSTransaction in Own Shares
4th Dec 20237:00 amRNSTransaction in Own Shares
1st Dec 20237:00 amRNSTransaction in Own Shares
30th Nov 20237:00 amRNSTransaction in Own Shares
29th Nov 20237:00 amRNSTransaction in Own Shares
28th Nov 20237:00 amRNSTransaction in Own Shares
23rd Nov 20234:51 pmRNSDirector/PDMR Shareholding
31st Oct 20233:53 pmRNSExercise of Awards
17th Oct 20231:00 pmRNSResult of AGM
10th Oct 20237:00 amRNSTransaction in Own Shares
9th Oct 20237:00 amRNSTransaction in Own Shares
5th Oct 20231:40 pmRNSDirector/PDMR Shareholding
5th Oct 20237:00 amRNSShare Buyback Programme
2nd Oct 20237:00 amRNSDividend currency entitlement
19th Sep 20237:00 amRNSFinal Results
13th Sep 20231:00 pmRNSLondon Investor Event
12th Sep 20234:17 pmRNSNotice of AGM - Correction
12th Sep 20237:00 amRNSNotice of AGM
4th Sep 20237:00 amRNSSettlement in Australian class action
30th Aug 20237:00 amRNSNotice of Results
27th Jul 20237:00 amRNSUpdate following Supreme Court ruling
20th Jul 20237:00 amRNSProgress on Fund I investment
18th Jul 20237:00 amRNSFair Value Accounting and Dividend Payment
22nd Jun 20237:00 amRNSSuccessful resolution of balance sheet investment
19th Jun 20237:00 amRNSResolution of Investment
15th May 20239:48 amRNSSettlement in Australian class action
3rd Apr 20237:00 amRNSResolution of investment
20th Mar 20237:00 amRNSDirector/PDMR Shareholding
14th Mar 20237:00 amRNSHalf-year Report
9th Mar 20237:00 amRNSSettlement in Australian class action
27th Feb 20239:30 amRNSNotice of Results
23rd Feb 20237:00 amRNSProgress on direct balance sheet investment
20th Feb 20237:00 amRNSSuccessful settlement in the Carillion claim
20th Dec 20227:00 amRNSProgress on portfolio of Investments
29th Nov 20227:00 amRNSDirector/PDMR Shareholding
16th Nov 20227:04 amRNSResult of AGM
20th Oct 20227:00 amRNSNew Litigation Finance Agreement
19th Oct 20229:26 amRNSNotice of AGM
13th Oct 20223:44 pmRNSIncentive Awards
4th Oct 20227:00 amRNSSecond close of Global Alternative Returns Fund II
29th Sep 20229:30 amRNSDirector/PDMR Shareholding
26th Sep 20226:00 pmRNSDirector/PDMR Shareholding
20th Sep 20227:00 amRNSFinal Results
23rd Aug 20227:00 amRNSNotice of Results
15th Jul 20228:22 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.